Literature DB >> 6329968

Transformation affects superoxide dismutase activity.

D P Loven, D L Guernsey, L W Oberley.   

Abstract

A human, aging lung fibroblast cell strain manifested both copper-zinc superoxide dismutase activity (CuZn-SOD) and manganese-containing superoxide dismutase activity (MnSOD), and these activities were found to be modulated by physiological concentrations of thyroid hormone. The immortal cell lines examined, whether normal or malignant, had no MnSOD activity. The immortal normal cell lines examined had CuZnSOD activity which was modulated by thyroid hormone, whereas the immortal malignant cell lines had CuZnSOD activity which was not affected, or not as strongly affected, by the presence of thyroid hormone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329968     DOI: 10.1002/ijc.2910330612

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  In vitro modulation of antioxidant enzymes in normal and malignant renal epithelium.

Authors:  A H Yang; T D Oberley; L W Oberley; S M Schmid; K B Cummings
Journal:  In Vitro Cell Dev Biol       Date:  1987-08

Review 2.  Role of antioxidant enzymes in cell immortalization and transformation.

Authors:  L W Oberley; T D Oberley
Journal:  Mol Cell Biochem       Date:  1988-12       Impact factor: 3.396

3.  NADPH oxidase activation is required in reactive oxygen species generation and cell transformation induced by hexavalent chromium.

Authors:  Xin Wang; Young-Ok Son; Qingshan Chang; Lijuan Sun; J Andrew Hitron; Amit Budhraja; Zhuo Zhang; Zunji Ke; Fei Chen; Jia Luo; Xianglin Shi
Journal:  Toxicol Sci       Date:  2011-07-08       Impact factor: 4.849

4.  Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase.

Authors:  F Okada; H Shionoya; M Kobayashi; T Kobayashi; H Tazawa; K Onuma; Y Iuchi; N Matsubara; T Ijichi; B Dugas; M Hosokawa
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.